Moderna COVID jab gets positive CHMP opinion
EMA panel backs bivalent vaccine targeting Omicron subvariants BA.4 and BA.5
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Moderna's bivalent COVID-19 vaccine, mRNA-1273.222, targeting the Omicron BA.4 and BA.5 subvariants.
The CHMP's positive opinion is based on data from a clinical trial involving over 800 adults who had previously received two or three doses of an authorized COVID-19 vaccine. The study found that the bivalent vaccine produced a strong immune response against both the original SARS-CoV-2 virus and the Omicron BA.4 and BA.5 subvariants.
The CHMP's recommendation will now be reviewed by the European Commission, which is expected to make a final decision on whether to grant marketing authorization for the bivalent vaccine in the coming weeks. If approved, the Moderna bivalent vaccine would be the second COVID-19 vaccine to be authorized in the EU that targets the Omicron subvariants.
The CHMP's positive opinion is a significant development in the fight against COVID-19. The Omicron subvariants have been responsible for a significant increase in cases in Europe and around the world, and the bivalent vaccine is expected to provide better protection against these variants than the original vaccines.
The Moderna bivalent vaccine is expected to be available in the EU in the coming months. The vaccine will be available to adults who have completed their primary course of COVID-19 vaccination.
Benefits of the Moderna Bivalent Vaccine
- Provides strong protection against the Omicron BA.4 and BA.5 subvariants
- Is safe and well-tolerated
- Is easy to administer
Who Should Get the Moderna Bivalent Vaccine?
The Moderna bivalent vaccine is recommended for adults who have completed their primary course of COVID-19 vaccination.
How to Get the Moderna Bivalent Vaccine
The Moderna bivalent vaccine will be available at vaccination centers and pharmacies throughout the EU.
Conclusion
The CHMP's positive opinion for the Moderna bivalent vaccine is a significant development in the fight against COVID-19. The bivalent vaccine is expected to provide better protection against the Omicron subvariants than the original vaccines and will be available in the EU in the coming months.
تعليقات